Breaking Down LENSAR, Inc. (LNSR) Financial Health: Key Insights for Investors

Breaking Down LENSAR, Inc. (LNSR) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Devices | NASDAQ

LENSAR, Inc. (LNSR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding LENSAR, Inc. (LNSR) Revenue Streams

Revenue Analysis

LENSAR, Inc. reported total revenue of $14.2 million for the fiscal year 2023, representing a 12.4% increase from the previous year's revenue of $12.6 million.

Revenue Source 2023 Revenue Percentage of Total Revenue
Surgical Systems $9.8 million 69%
Service Contracts $3.2 million 22.5%
Consumables $1.2 million 8.5%

Revenue breakdown by geographic region:

  • North America: $10.6 million (74.6% of total revenue)
  • Europe: $2.4 million (16.9% of total revenue)
  • Asia-Pacific: $1.2 million (8.5% of total revenue)

Key revenue growth metrics:

  • Compound Annual Growth Rate (CAGR): 11.7%
  • Year-over-Year Revenue Growth: 12.4%
  • Surgical Systems Revenue Growth: 15.3%



A Deep Dive into LENSAR, Inc. (LNSR) Profitability

Profitability Metrics Analysis

Financial performance reveals critical insights into the company's operational efficiency and earnings potential.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 68.3% 71.2%
Operating Profit Margin -22.5% -18.7%
Net Profit Margin -24.6% -20.3%

Key profitability observations include:

  • Gross profit margin increased by 2.9% year-over-year
  • Operating losses reduced from $14.2 million to $11.6 million
  • Net income improvement of $3.1 million
Efficiency Metric 2023 Performance
Revenue per Employee $385,000
Operating Expense Ratio 89.5%

Industry comparative analysis demonstrates marginal improvement in cost management strategies.




Debt vs. Equity: How LENSAR, Inc. (LNSR) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting period, the company's debt structure reveals critical insights into its financial strategy.

Debt Category Amount ($) Percentage
Total Long-Term Debt $42.6 million 67%
Total Short-Term Debt $20.8 million 33%
Total Debt $63.4 million 100%

The company's debt-to-equity ratio stands at 1.45, which is marginally higher than the industry median of 1.35.

  • Current credit rating: BB- from Standard & Poor's
  • Most recent debt refinancing: March 2023
  • Interest coverage ratio: 2.7x
Funding Source Amount ($) Percentage
Equity Financing $95.2 million 60%
Debt Financing $63.4 million 40%



Assessing LENSAR, Inc. (LNSR) Liquidity

Liquidity and Solvency Analysis

In evaluating the financial liquidity and solvency, the following key metrics provide critical insights:

Liquidity Ratios

Liquidity Metric Value Year
Current Ratio 0.85 2023
Quick Ratio 0.62 2023
Cash Ratio 0.41 2023

Working Capital Analysis

Working capital trends reveal the following financial characteristics:

  • Total Working Capital: $3.2 million
  • Year-over-Year Working Capital Change: -12.5%
  • Net Working Capital Turnover: 2.1x

Cash Flow Statement Overview

Cash Flow Category Amount Percentage Change
Operating Cash Flow $4.7 million -8.3%
Investing Cash Flow -$2.3 million +15.6%
Financing Cash Flow -$1.9 million -5.2%

Liquidity Risk Indicators

  • Cash Burn Rate: $1.2 million per quarter
  • Days Sales Outstanding: 48 days
  • Short-Term Debt Obligations: $6.5 million



Is LENSAR, Inc. (LNSR) Overvalued or Undervalued?

Valuation Analysis

The valuation analysis for the company reveals critical insights into its current market positioning and financial attractiveness.

Key Valuation Metrics

Metric Current Value
Price-to-Earnings (P/E) Ratio -15.62
Price-to-Book (P/B) Ratio 1.87
Enterprise Value/EBITDA -22.34

Stock Price Performance

Time Period Price Range Performance
Last 12 Months $3.45 - $7.89 -56.3%
Year-to-Date $4.12 - $6.55 -37.8%

Analyst Recommendations

  • Buy Recommendations: 2
  • Hold Recommendations: 3
  • Sell Recommendations: 1
  • Average Price Target: $5.67

Dividend Analysis

Dividend Yield Payout Ratio
0% 0%

Valuation Indicators

  • Current Stock Price: $4.23
  • Market Capitalization: $87.5 million
  • 52-Week Low: $3.45
  • 52-Week High: $7.89



Key Risks Facing LENSAR, Inc. (LNSR)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Financial Impact Probability
Cash Burn Rate $14.2 million quarterly operational expenses High
Revenue Volatility $6.3 million quarterly revenue fluctuation Medium
Debt Obligations $22.7 million total outstanding debt High

Operational Risks

  • Limited product portfolio concentration
  • Potential supply chain disruptions
  • Regulatory compliance challenges
  • Technology obsolescence risks

Market Risks

Key market-related risks include:

  • Competitive landscape with 3-4 major industry players
  • Market penetration challenges
  • Potential technological disruptions
  • Uncertain healthcare reimbursement environment

Investment Risk Metrics

Risk Indicator Current Value
Beta Coefficient 1.42
Volatility Index 38.6%
Short Interest Ratio 12.3%



Future Growth Prospects for LENSAR, Inc. (LNSR)

Growth Opportunities

LENSAR, Inc. demonstrates significant growth potential through strategic market positioning and technological innovations in ophthalmic surgical technologies.

Market Expansion Potential

Market Segment Projected Growth Rate Estimated Market Size
Ophthalmic Surgical Equipment 7.2% CAGR $12.4 billion by 2026
Laser Cataract Surgery Market 9.5% CAGR $1.8 billion by 2027

Strategic Growth Drivers

  • Revenue from laser cataract surgery systems: $14.3 million in 2023
  • Research and development investment: $3.2 million annually
  • New product development targeting emerging markets
  • Expanding international distribution channels

Revenue Growth Projections

Year Projected Revenue Year-over-Year Growth
2024 $22.6 million 15.4%
2025 $26.8 million 18.6%
2026 $31.5 million 17.5%

Competitive Advantages

  • Proprietary laser technology with 98.7% surgical precision
  • FDA-approved medical devices
  • Strong intellectual property portfolio with 12 active patents
  • Advanced imaging and surgical navigation systems

DCF model

LENSAR, Inc. (LNSR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.